SOPHiA GENETICS Reports 19% Revenue Growth, Secures $25M Loan, Wins Key Patent Ruling

summarizeSummary

SOPHiA GENETICS reported 19% revenue growth in 2025 but increased net losses, while securing $25.0 million in new loan commitments and selling $15.2 million via an ATM program. The company also achieved a favorable interim ruling in a patent dispute and announced a strategic partnership with Myriad Genetics.

check_boxKey Events

• Annual Financial Performance

  Reported 2025 revenue of $77.3 million, a 19% increase from $65.2 million in 2024. Net loss expanded to $79.0 million in 2025 from $62.5 million in 2024, with cash and cash equivalents decreasing to $70.3 million.

• Secured Additional Financing

  Entered into a January 23, 2026 amendment to the Perceptive Credit Agreement, providing $25.0 million in additional term loan commitments, with $12.5 million immediately available. The company also sold 2,795,485 ordinary shares for $14.1 million through its ATM program through February 20, 2026, adding to $1.1 million sold in 2025.

• Favorable Patent Litigation Outcome

  The Unified Patent Court (UPC) Paris Local Division rejected Guardant Health's application for provisional measures in a patent infringement suit and ordered Guardant to pay an interim award of EUR 400,000 (approximately $470,080) by March 10, 2026. Guardant has appealed this decision.

• Strategic Partnership with Myriad Genetics

  Announced a September 2025 partnership with Myriad Genetics to develop a companion diagnostic (CDx) liquid biopsy assay, with Myriad also planning to adopt the SOPHiA DDM platform for clinical lab testing.

auto_awesomeAnalysis

SOPHiA GENETICS SA's annual report for 2025 reveals a 19% increase in revenue to $77.3 million, driven by platform usage, but also an expanded net loss of $79.0 million and a decrease in cash reserves to $70.3 million. The company has actively addressed its liquidity needs by securing an additional $25.0 million in term loan commitments and selling $15.2 million in shares through its at-the-market (ATM) program. A significant positive development is the interim victory in the Guardant Health patent litigation, where the Unified Patent Court rejected Guardant's provisional measures and ordered them to pay EUR 400,000 in costs. Furthermore, the vacating of the FDA's LDT Final Rule removes a potential regulatory burden, and a new partnership with Myriad Genetics for companion diagnostic development signals strategic growth. These operational and legal wins, alongside successful capital raises, are crucial for the company's continued growth despite ongoing losses.